Given our previous finding that splicing factor mutations confer sensitivity to ATR inhibition [32], we examined the response of SRSF2-mutant AML samples to ATR inhibitors and its downstream effector kinases, CHK1 and WEE1. Here, ATR is linked to acute myeloid leukemia.